ArdorComm Media News Network
June 18, 2026
Novartis India has announced the launch of Pluvicto, India’s first regulatory-approved radioligand therapy designed for eligible patients suffering from PSMA-positive metastatic prostate cancer, marking a significant advancement in precision oncology treatment in the country.
The newly introduced therapy, Pluvicto (lutetium-177Lu vipivotide tetraxetan), works by specifically targeting prostate cancer cells while reducing damage to surrounding healthy tissues. The treatment offers a new approach for managing advanced-stage prostate cancer, a condition that continues to place a growing health burden on patients and families across India.
Prostate cancer is emerging as one of the fastest-rising cancers among Indian men, with nearly 250,000 cases reported annually, particularly affecting urban populations. According to the company, nearly half of all diagnosed patients are detected at the metastatic stage, making treatment more challenging and limiting available therapeutic options.
Judith Love, Region Head for Asia Pacific, Middle East, and Africa at Novartis, highlighted that India remains a key market for the company as demand grows for advanced cancer treatments. She noted that the introduction of Pluvicto reflects Novartis’ commitment to expanding access to globally recognized innovations while leveraging India’s rapidly growing nuclear medicine infrastructure.
Amitabh Dube, Country President and Managing Director of Novartis India, emphasized that many prostate cancer patients in India are diagnosed only after the disease progresses significantly, reducing treatment effectiveness. He stated that bringing Pluvicto to India addresses the increasing demand for precision oncology solutions and supports the future development of nuclear medicine-based therapies.
India’s nuclear medicine ecosystem has expanded considerably over the past decade, with more than 250 nuclear medicine centres currently operational nationwide. Novartis plans to work closely with hospitals, oncologists, nuclear medicine specialists, and healthcare institutions to strengthen treatment access and ensure readiness for radioligand therapy adoption.
Pluvicto will be introduced through selected hospitals and nuclear medicine centres across India under Novartis’ partnership-driven strategy to improve access to next-generation cancer care.
Source: The Hindu